CN115260176B - 一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 - Google Patents
一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115260176B CN115260176B CN202211070004.8A CN202211070004A CN115260176B CN 115260176 B CN115260176 B CN 115260176B CN 202211070004 A CN202211070004 A CN 202211070004A CN 115260176 B CN115260176 B CN 115260176B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- chloroform
- nmr
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- -1 Pyrazole amide Chemical class 0.000 title claims abstract description 34
- 125000002971 oxazolyl group Chemical group 0.000 title claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 174
- 238000006243 chemical reaction Methods 0.000 claims abstract description 36
- 239000003960 organic solvent Substances 0.000 claims abstract description 20
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 9
- 239000011230 binding agent Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 16
- 230000000843 anti-fungal effect Effects 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000004440 column chromatography Methods 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 10
- 238000005660 chlorination reaction Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 241000221696 Sclerotinia sclerotiorum Species 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- SAFIYTUATMNFHY-UHFFFAOYSA-N 2-cyano-3-ethoxypropanoic acid Chemical compound CCOCC(C#N)C(O)=O SAFIYTUATMNFHY-UHFFFAOYSA-N 0.000 claims description 6
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000223221 Fusarium oxysporum Species 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 241000813090 Rhizoctonia solani Species 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- 229940126062 Compound A Drugs 0.000 claims description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 4
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 claims description 2
- 244000061176 Nicotiana tabacum Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 161
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 95
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 39
- 239000007787 solid Substances 0.000 description 39
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 37
- XAMBIJWZVIZZOG-UHFFFAOYSA-N (4-methylphenyl)hydrazine Chemical compound CC1=CC=C(NN)C=C1 XAMBIJWZVIZZOG-UHFFFAOYSA-N 0.000 description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 238000004293 19F NMR spectroscopy Methods 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- XXNOGQJZAOXWAQ-UHFFFAOYSA-N 4-chlorophenylhydrazine Chemical group NNC1=CC=C(Cl)C=C1 XXNOGQJZAOXWAQ-UHFFFAOYSA-N 0.000 description 11
- 241000123650 Botrytis cinerea Species 0.000 description 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 10
- 241000223600 Alternaria Species 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 8
- YMMCBGIHBVKZGD-UHFFFAOYSA-N (4-fluorophenyl)methylhydrazine Chemical group NNCC1=CC=C(F)C=C1 YMMCBGIHBVKZGD-UHFFFAOYSA-N 0.000 description 7
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 7
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 7
- 239000005740 Boscalid Substances 0.000 description 6
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 description 6
- 229940118790 boscalid Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- VOIZNVUXCQLQHS-UHFFFAOYSA-N 3-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1 VOIZNVUXCQLQHS-UHFFFAOYSA-N 0.000 description 4
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 4
- FQXQBFUUVCDIRK-UHFFFAOYSA-N 3-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-N 0.000 description 4
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 4
- SWKPKONEIZGROQ-UHFFFAOYSA-N 4-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluic acid Chemical compound CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000005746 Carboxin Substances 0.000 description 3
- 241000227653 Lycopersicon Species 0.000 description 3
- 241000221662 Sclerotinia Species 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- GYSSRZJIHXQEHQ-UHFFFAOYSA-N carboxin Chemical compound S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 GYSSRZJIHXQEHQ-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 244000000004 fungal plant pathogen Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- FFKGOJWPSXRALK-UHFFFAOYSA-N 3-(3-chlorophenyl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CC(Cl)=C1 FFKGOJWPSXRALK-UHFFFAOYSA-N 0.000 description 2
- ISMMYAZSUSYVQG-ZZXKWVIFSA-N 4-Fluorocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C=C1 ISMMYAZSUSYVQG-ZZXKWVIFSA-N 0.000 description 2
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 2
- UJDLCTNVHJEBDG-UHFFFAOYSA-N 6-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)N=C1 UJDLCTNVHJEBDG-UHFFFAOYSA-N 0.000 description 2
- 241000223602 Alternaria alternata Species 0.000 description 2
- 241000228438 Bipolaris maydis Species 0.000 description 2
- 229910020323 ClF3 Inorganic materials 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241001512566 Valsa mali Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZXBMIRYQUFQQNX-UHFFFAOYSA-N (4-fluorophenyl)hydrazine Chemical group NNC1=CC=C(F)C=C1 ZXBMIRYQUFQQNX-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- GOFJDXZZHFNFLV-UHFFFAOYSA-N 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]pyrazole-4-carboxamide Chemical compound CC(C)CC(C)C1=CC=CC=C1NC(=O)C1=C(F)N(C)N=C1C GOFJDXZZHFNFLV-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000412366 Alternaria mali Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000005738 Bixafen Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000005788 Fluxapyroxad Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- XQJQCBDIXRIYRP-UHFFFAOYSA-N N-{2-[1,1'-bi(cyclopropyl)-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1pyrazole-4-carboxamide Chemical compound FC(F)C1=NN(C)C=C1C(=O)NC1=CC=CC=C1C1C(C2CC2)C1 XQJQCBDIXRIYRP-UHFFFAOYSA-N 0.000 description 1
- 239000005815 Penflufen Substances 0.000 description 1
- 239000005834 Sedaxane Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- LDLMOOXUCMHBMZ-UHFFFAOYSA-N bixafen Chemical compound FC(F)C1=NN(C)C=C1C(=O)NC1=CC=C(F)C=C1C1=CC=C(Cl)C(Cl)=C1 LDLMOOXUCMHBMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- SXSGXWCSHSVPGB-UHFFFAOYSA-N fluxapyroxad Chemical compound FC(F)C1=NN(C)C=C1C(=O)NC1=CC=CC=C1C1=CC(F)=C(F)C(F)=C1 SXSGXWCSHSVPGB-UHFFFAOYSA-N 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical group CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- YBKGERLDRMINOV-UHFFFAOYSA-N oxathiine Chemical compound O1SC=CC=C1 YBKGERLDRMINOV-UHFFFAOYSA-N 0.000 description 1
- 230000003032 phytopathogenic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- RCIGDGBXEMECGY-UHFFFAOYSA-N pyridin-3-ylhydrazine Chemical group NNC1=CC=CN=C1 RCIGDGBXEMECGY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P3/00—Fungicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用,涉及药物化学技术领域。通过将芳香酸、缩合剂、有机溶剂和缚酸剂混合后得到反应体系,将化合物F加入到所述反应体系中反应,萃取得到所述含噁唑基团的吡唑酰胺类衍生物。本发明制备了38种不同的衍生物,并提供了这些衍生物的化学结构同时还验证了其抗菌活性,表现出广谱的抑菌活性。
Description
技术领域
本发明涉及药物化学技术领域,特别是涉及一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用。
背景技术
琥珀酸脱氢酶抑制剂(SDHI)可以通过破坏嵌入线粒体内膜的琥珀酸脱氢酶(SDH)来破坏线粒体柠檬酸循环和呼吸链电子传递,从而抑制病原真菌的生长和繁殖。在过去的半个世纪中,实践探索已经证实SDHIs具有独特的作用模式,广谱和优异的抗真菌活性,其已被广泛用于控制谷物、蔬菜和水果的真菌感染。自20世纪60年代第一个SDHI类产品萎锈灵(Carboxin)上市以来,琥珀酸脱氢酶抑制剂的开发从未停止。迄今为止,已有24种琥珀酸脱氢酶抑制剂被杀真菌抗药性行动委员会(FRAC)商业化,包括oxathiin carboxin(1969年)、boscalid(2003年)、bixafen(2006年)、fluxapyroxad(2011年)、sedaxane(2011年)、penflufen(2012年)、flubenteram(2016年)和inpyrruxam(2017年)。然而,由于长期不科学和不受控制地滥用琥珀酸脱氢酶抑制剂,近年来植物病原真菌的耐药性变得日益严重。因此,迫切需要开发毒性更低且具有高效抗真菌活性的先导化合物。
发明内容
基于上述内容,本发明提供一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用。
为实现上述目的,本发明提供了如下方案:
本发明技术方案之一,一种含噁唑基团的吡唑酰胺类衍生物,结构式如下所示:
其中,R1为烷基、芳基、或杂芳基中的一种;R2为烷基、芳基、芳烯烃或杂芳烃;R3为氢或烷基。
本发明技术方案之二,上述的含噁唑基团的吡唑酰胺类衍生物的制备方法,包括以下步骤:
将芳香酸、缩合剂、有机溶剂和缚酸剂混合后得到反应体系,将化合物F加入到所述反应体系中反应,萃取得到所述含噁唑基团的吡唑酰胺类衍生物;
所述化合物F的结构式为
其中,R1为烷基、芳基或杂芳基中的一种;R3为氢或烷基。
进一步地,所述芳香酸为对氟苯甲酸、间氟苯甲酸、对氯苯甲酸、间氯苯甲酸、对溴苯甲酸、间溴苯甲酸、对甲基苯甲酸、间甲基苯甲酸、对三氟甲基苯甲酸、间三氟甲基苯甲酸、苯甲酸、6-氟烟酸、6-氯烟酸、3-氯肉桂酸、对氟肉桂酸或扁桃酸中的一种;
所述缩合剂为2-(7-氮杂苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯;
所述有机溶剂为二氯甲烷、乙腈、四氢呋喃、甲苯、甲醇、乙醇、乙酸乙酯、1,2-二氯乙烷、N,N-二甲基甲酰胺、N-甲基吡咯烷酮或二甲基亚砜中的一种;
所述缚酸剂为三乙胺或N,N-二异丙基乙胺。
进一步地,所述化合物F、芳香酸、缩合剂和缚酸剂的摩尔当量比为1:1.2:1.5:1.5;
所述混合后搅拌3小时得到反应体系;
所述反应的过程中利用薄层色谱点板确定反应终点;
所述萃取后还包括依次干燥、抽滤、减压蒸馏和柱层析分离的步骤。
进一步地,所述萃取具体为:反应结束后,依次采用饱和氯化铵溶液、饱和碳酸氢钠溶液、饱和食盐水和乙酸乙酯萃取;所述柱层析分离具体为:100-200目的柱层析硅胶粉,洗脱试剂:石油醚:乙酸乙酯为2:1;所述干燥采用的干燥试剂为无水硫酸钠;
进一步地,所述化合物F的制备方法包括以下步骤:
以化合物肼与2-氰基-3-乙氧基丙酸酯为起始底物进行缩合,依次经过水解反应、氯代反应、取代反应、氯代反应和环化反应,制备得到的所述化合物F;
制备路线如下:
进一步地,所述化合物F的制备方法包括以下步骤:
步骤1,将化合物肼与2-氰基-3-乙氧基丙酸酯加入到有机溶剂中进行水解反应得到化合物A;
步骤2,将所述化合物A与碱加入到有机溶剂中进行水解反应,得到化合物B;
步骤3,将所述化合物B溶解于有机溶剂后加入氯化亚砜进行氯代反应,得到化合物C;
步骤4,将所述化合物C和吡啶溶解在有机溶剂中得到混合溶液,向所述混合溶液中滴加醇胺溶液进行取代反应,得到化合物D;
步骤5,将所述化合物D溶解在有机溶剂中,之后加入氯化亚砜进行氯代反应,得到化合物E;
步骤6,将所述化合物E和碱加入到有机溶剂中进行环化反应,得到所述化合物F。
进一步地,步骤1中,所述水解反应具体为70-85℃回流反应2-4小时,所述化合物肼与2-氰基-3-乙氧基丙酸酯摩尔当量比为1:1-3;
步骤2中,所述水解反应具体为70-80℃回流反应2-4小时;
步骤3中,所述化合物B与所述氯化亚砜摩尔当量比为1:1.25-1.5,所述氯代反应为30-40℃回流反应10-14小时。
进一步地,步骤4中,所述化合物C与醇胺的摩尔当量比为1:1-3,取代反应温度为0℃,所述醇胺为乙醇胺或丙醇胺;
步骤5中,所述氯代反应具体为30-40℃条件下反应10-14h,所述化合物D与所述氯化亚砜的摩尔当量比为1:1.2;
步骤6中,所述环化反应具体为50-90℃回流反应3-4h;所述化合物E与碱的摩尔当量比为1:1.5。
进一步地,步骤1-6中,所述有机溶剂独立的选自二氯甲烷、乙腈、四氢呋喃、甲苯、甲醇、乙醇、乙酸乙酯、1,2-二氯乙烷、N,N-二甲基甲酰胺、N-甲基吡咯烷酮或二甲基亚砜中的一种;
步骤2中以及步骤6中,所述碱独立的选自碳酸铯、叔丁醇钾、叔丁醇钠、氢氧化钠、氢氧化钾或碳酸钾中的一种。
本发明技术方案之三,上述的含噁唑基团的吡唑酰胺类衍生物在制备抗真菌药物中的应用。
本发明公开了以下技术效果:
本发明公开的含噁唑基团的吡唑酰胺类衍生物是以中间体F和酸为原料,2-(7-氮杂苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯(HATU)为缩合剂,在有机溶剂(DMF)中,并用三乙胺作为缚酸剂,即可通过一步反应合成目标产物,该合成方法为首次出现,并且后处理过程简单。
具体实施方式
现详细说明本发明的多种示例性实施方式,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。
应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。
在不背离本发明的范围或精神的情况下,可对本发明说明书的具体实施方式做多种改进和变化,这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见的。本申请说明书和实施例仅是示例性的。
关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等,均为开放性的用语,即意指包含但不限于。
本发明实施例中的柱层析条件为:100-200目的柱层析硅胶粉。
本发明实施例中标注的摩尔数表示的是反应体系中该物质的用量。
实施例1化合物H1的制备
化合物H1的合成路线如下所示:
(1)由2-氰基-3-乙氧基丙酸酯(0.06mol)和对甲基苯肼(0.05mol)的乙醇溶液在85℃下回流3小时得到化合物A1的粗产物,反应完成后减压蒸馏除去乙醇,用乙酸乙酯/石油醚(3:1=v/v)进行柱层析,得到化合物A1。
(2)向化合物A1(0.05mol)的乙醇溶液中加入氢氧化钠水溶液(0.06mol),80℃回流3小时,TLC监测反应,反应完成后将粗产物减压蒸馏,加入盐酸(0.06mol)析出固体,抽滤干燥,得到化合物B1。
(3)将干燥后的化合物B1(20mmol)与二氯甲烷(20mL)混合,缓慢滴加SOCl2(25mmol)溶解,40℃回流反应12小时,TLC监测反应,通过减压浓缩获得化合物C1。
(4)将化合物C1(10mmol)和吡啶(0.1mmol)的混合物溶解在四氢呋喃(15mL)中,然后将混合物缓慢滴加到乙醇胺(12mmol)的四氢呋喃(5mL)溶液中,并在0℃下反应24小时,TLC监测反应。将反应混合物减压浓缩除去四氢呋喃,有机相用二氯甲烷和水萃取,用无水硫酸钠干燥,抽滤,减压蒸馏。使用乙酸乙酯/石油醚(1:4=v/v)进行柱层析以获得化合物D1。
(5)将SOCl2(12mmol)缓慢加入化合物D1(10mmol)的二氯甲烷溶液(20mL)中,并在40℃下回流反应12小时,TLC监测反应。反应完成后,减压浓缩除去二氯甲烷,得到粗产物的有机溶液用乙酸乙酯和水萃取,用无水硫酸钠干燥,抽滤,减压蒸馏。使用乙酸乙酯/石油醚(1:1=v/v)进行柱层析以获得化合物E1。
(6)将干燥的化合物E1(20mmol)、氢氧化钠(30mmol)在无水乙醇中80℃回流反应3小时,随后慢慢冷却到室温搅拌过夜,TLC追踪反应,反应结束后用二氯甲烷萃取有机相,用无水硫酸钠干燥,抽滤后减压蒸馏除去有机相,使用乙酸乙酯/石油醚(1:2v/v)进行柱层析分离以获得目标化合物F1。
(7)将对氟苯甲酸(1.2mmol)、2-(7-氮杂苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯(HATU)(1.5mmol)、三乙胺(Et3N)(2mmol)在无水DMF溶液中搅拌3小时,随后将干燥的化合物F1(1mmol)投入反应溶液中搅拌过夜,TLC追踪反应,反应结束后用乙酸乙酯萃取有机相,用无水硫酸钠干燥,抽滤后减压蒸馏除去有机相,使用乙酸乙酯/石油醚(1:2v/v)进行柱层析分离以获得目标化合物H1。
化合物H1:N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-4-氟苯甲酰胺,结构式如下所示:
化合物H1为淡黄色固体,产率为69%;mp,136-137℃;1H NMR(600MHz,Chloroform-d)δ8.03–7.82(m,3H,Ar-H,Ph-H),7.42(d,J=6.8Hz,2H,Ph-H),7.19(d,J=8.1Hz,2H,Ph-H),7.10(d,J=8.2Hz,2H,Ph-H),4.31(t,J=9.2Hz,2H,-CH2-),3.89(t,J=9.1Hz,2H,-CH2-),2.35(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ165.3(d,J=253.68Hz),163.9,160.5,138.6,138.4,138.0,137.6,130.4(d,J=9.1Hz),129.6,129.2(d,J=3.0Hz),122.6,115.8(d,J=21.1Hz),101.9,67.0,54.0,21.1.19F NMR(376MHz,Chloroform-d)δ-106.25(s).HRMS(ESI)calculated for C20H18FN4O2[M+H]+,365.1408;found,365.1416.
实施例2化合物H2的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为间氟苯甲酸。得到化合物H2为N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-3-氟苯甲酰胺,结构式如下所示:
化合物H2为淡黄色固体,产率为65%;mp,134-135℃;1H NMR(600MHz,Chloroform-d)δ7.91(d,J=6.0Hz,1H,Ar-H),7.70(t,J=7.5Hz,1H,Ph-H),7.61(d,J=7.5Hz,1H,Ph-H),7.50–7.36(m,3H,Ph-H),7.28–7.19(m,3H,Ph-H),4.40–4.29(m,2H,-CH2-),4.01–3.89(m,2H,-CH2-),2.36(d,J=6.2Hz,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.5,162.7(d,J=247.6Hz),160.5,138.6,138.3,138.1,137.6,130.4(d,J=7.6Hz),129.7,123.4(d,J=3.0Hz),122.6,119.5(d,J=21.1Hz),115.1(d,J=24.2Hz),67.0,21.1.19F NMR(376MHz,Chloroform-d)δ-111.38(s).HRMS(ESI)calculated for C20H18FN4O2[M+H]+,365.1408;found,365.1418.
实施例3化合物H3的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为对氯苯甲酸。得到化合物H3为4-氯-N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H3为淡黄色固体,产率为70%;mp,166-167℃;1H NMR(600MHz,Chloroform-d)δ7.89(s,1H,Ar-H),7.83(d,J=8.5Hz,2H,Ph-H),7.41(t,J=8.5Hz,4H,Ph-H),7.20(d,J=8.3Hz,2H,Ph-H),4.32(t,J=7.9Hz,2H,-CH2-),3.90(t,J=9.1Hz,2H,-CH2-),2.35(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.8,160.5,138.9,138.6,138.3,138.0,137.6,131.4,129.6,129.3,129.0,122.6,101.8,67.0,54.0,21.1.HRMS(ESI)calculated for C20H18ClN4O2[M+H]+,381.1113;found,381.1109.
实施例4化合物H4的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为间氯苯甲酸。得到化合物H4为3-氯-N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H4为淡黄色固体,产率为75%;mp,155-156℃;1H NMR(600MHz,Chloroform-d)δ7.90(d,J=9.3Hz,2H,Ph-H),7.77(d,J=7.6Hz,1H,Ar-H),7.51(d,J=8.6Hz,1H,Ph-H),7.48–7.32(m,3H,Ph-H),7.21(d,J=8.5Hz,2H,Ph-H),4.35(t,J=8.0Hz,2H,-CH2-),3.97(t,J=12.4Hz,2H,-CH2-),2.36(d,J=9.5Hz,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ13C NMR(151MHz,Chloroform-d)δ163.5,160.5,138.6,138.3,137.7,135.0,134.8,132.5,130.0,129.7,128.3,125.8,122.6,101.7,67.1,54.0,21.1.HRMS(ESI)calculated for C20H18ClN4O2[M+H]+,381.1113;found,381.1117.
实施例5化合物H5的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为对溴苯甲酸。得到化合物H5为4-溴-N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H5为淡黄色固体,产率为61%;mp,84-85℃;1H NMR(600MHz,Chloroform-d)δ7.90(s,1H,Ar-H),7.76(d,J=6.8Hz,2H,Ph-H),7.58(d,J=8.6Hz,2H,Ph-H),7.42(d,J=8.4Hz,2H,Ph-H),7.20(d,J=8.1Hz,2H,Ph-H),4.34(t,J=9.4Hz,2H,-CH2-),3.93(t,J=9.4Hz,2H,-CH2-),2.35(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.9,159.9,139.1,138.6,138.4,138.1,137.6,132.00,131.9,130.2,129.6,129.4,127.4,124.0,122.6,122.0,101.7,67.1,54.4,21.6.HRMS(ESI)calculated for C20H18BrN4O2[M+H]+,425.0608;found,425.0618.
实施例6化合物H6的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为间溴苯甲酸。得到化合物H6为3-溴-N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H6为淡黄色固体,产率为59%;mp,142-143℃;1H NMR(600MHz,Chloroform-d)δ8.04(s,1H,Ar-H),7.90–7.79(m,2H,Ph-H),7.65–7.58(m,1H,Ph-H),7.38(d,J=8.3Hz,2H,Ph-H),7.26(t,J=7.9Hz,1H,Ph-H),7.21(d,J=8.0Hz,2H,Ph-H),4.27(t,J=9.4Hz,2H,-CH2-),3.81(t,J=9.3Hz,2H,-CH2-),2.36(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.7,160.4,139.1,138.8,138.1,137.8,137.6,135.2,134.9,131.1,130.2,130.1,129.7,126.3,124.0,122.8,102.6.HRMS(ESI)calculated for C20H18BrN4O2[M+H]+,425.0608;found,425.0617.
实施例7化合物H7的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为对甲基苯甲酸。得到化合物H7为N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-4-甲基苯甲酰胺,结构式如下所示:
化合物H7为淡黄色固体,产率为66%;mp,148-149℃;1H NMR(600MHz,Chloroform-d)δ7.90(s,1H,Ar-H),7.80(d,J=8.4Hz,2H,Ph-H),7.45(d,J=8.0Hz,2H,Ph-H),7.25(d,J=7.0Hz,2H,Ph-H),7.19(d,J=8.0Hz,2H,Ph-H),4.33(t,J=9.5Hz,2H,-CH2-),3.95(t,J=9.4Hz,2H,-CH2-),2.41(s,3H,-CH3),2.34(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ164.72,160.38,143.13,138.73,138.55,138.27,137.39,130.28,129.60,129.36,127.90,122.50,101.56,66.95,54.08,21.49,21.10.HRMS(ESI)calculated forC21H21N4O2[M+H]+,361.1659;found,361.1657.
实施例8化合物H8的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为间甲基苯甲酸。得到化合物H8为N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-3-甲基苯甲酰胺,结构式如下所示:
化合物H8淡黄色固体,产率为59%;mp,154-155℃;1H NMR(600MHz,Chloroform-d)δ7.90(s,1H,Ar-H),7.70(d,J=12.7Hz,2H,Ph-H),7.45(d,J=8.4Hz,2H,Ph-H),7.35(d,J=7.0Hz,2H,Ph-H),7.19(d,J=8.1Hz,2H,Ph-H),4.34(t,J=9.4Hz,2H,-CH2-),3.95(t,J=9.4Hz,2H,-CH2-),2.38(s,3H,-CH3),2.34(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ165.4,159.8,138.6,138.6,137.5,133.2,133.0,128.7,128.5,124.8,122.6,101.7,54.0,21.3,21.1.HRMS(ESI)calculated for C21H21N4O2[M+H]+,361.1659;found,361.1659.
实施例9化合物H9的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为对三氟甲基苯甲酸。得到化合物H9为N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-4-(三氟甲基)苯甲酰胺,结构式如下所示:
化合物H9为淡黄色固体,产率为59%;mp,90-91℃;1H NMR(600MHz,Chloroform-d)δ8.01(d,J=8.0Hz,2H,Ph-H),7.91(s,1H,Ar-H),7.69(d,J=8.0Hz,2H,Ph-H),7.42(d,J=8.6Hz,2H,Ph-H),7.21(d,J=8.1Hz,2H,Ph-H),4.34(t,J=9.2Hz,2H,-CH2-),3.91(t,J=9.5Hz,2H,-CH2-),2.36(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.5,160.5,138.7,138.1,138.0,137.8,136.2,134.0(q,J=33.2Hz),129.7,128.3,125.7(q,J=4.5Hz),123.5(q,J=273.3Hz),122.6,102.0,67.1,53.9,21.1.19F NMR(376MHz,Chloroform-d)δ-63.14(s).HRMS(ESI)calculated for C21H18F3N4O2[M+H]+,415.1376;found,415.1392.
实施例10化合物H10的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为间三氟甲基苯甲酸。得到化合物H10为N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-3-(三氟甲基)苯甲酰胺,结构式如下所示:
化合物H10为淡黄色固体,产率为70%;mp,85-86℃;1H NMR(600MHz,Chloroform-d)δ8.20(s,1H,Ar-H),8.08(d,J=7.2Hz,1H,Ph-H),7.89(s,1H,Ph-H),7.74(d,J=7.8Hz,1H,Ph-H),7.53(d,J=7.9Hz,1H,Ph-H),7.41(s,2H,Ph-H),7.22(d,J=7.7Hz,2H,Ph-H),4.29(t,J=10.0Hz,2H,-CH2-),3.83(t,J=6.6Hz,2H,-CH2-),2.36(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.6,160.5,138.8,137.8,137.7,133.7,131.2(q,J=33.2Hz),131.0,129.9,129.7,129.3,128.9(q,J=4.5Hz),125.0(q,J=4.5Hz),123.6(q,J=247.2Hz),122.8,102.4,67.1,53.7,21.1.19F NMR(376MHz,Chloroform-d)δ-62.88(s).HRMS(ESI)calculated for C21H18F3N4O2[M+H]+,415.1376;found,415.1372.
实施例11化合物H11的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼。得到化合物H11为N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)-4-氟苯甲酰胺,结构式如下所示:
化合物H11为淡黄色固体,产率为65%;mp,178-179℃;1H NMR(600MHz,Chloroform-d)δ8.04–7.80(m,3H,Ar-H,Ph-H),7.51(dd,J=8.7,1.7Hz,2H,Ph-H),7.38(dd,J=8.8,1.7Hz,2H,Ph-H),7.15(t,J=8.5Hz,2H,Ph-H),4.37(t,J=9.4Hz,2H,-CH2-),3.99(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ165.5(d,J=255.2Hz),163.7,160.5,139.3,139.0,138.8,133.4,130.3(d,J=9.1Hz),129.2,129.0(d,J=4.5Hz),116.0(d,J=22.7Hz),101.5,67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-105.80(s).HRMS(ESI)calculated for C19H15ClFN4O2[M+H]+,385.0862;found,385.0860.
实施例12化合物H12的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为间氟苯甲酸。得到化合物H12为N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)-3-氟苯甲酰胺,结构式如下所示:
化合物H12为淡黄色固体,产率为70%;mp,176-177℃;1H NMR(600MHz,Chloroform-d)δ7.92(s,1H,Ar-H),7.70(d,J=7.9Hz,1H,Ph-H),7.61(d,J=9.3Hz,1H,Ph-H),7.51(d,J=8.7Hz,2H,Ph-H),7.47(t,J=7.2Hz,1H,Ph-H),7.38(d,J=8.8Hz,2H,Ph-H),7.29(d,J=7.9Hz,1H,Ph-H),4.39(t,J=9.3Hz,2H,-CH2-),4.01(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.5,161.2(d,J=235.6Hz),160.4,139.3,138.8,138.8,135.1,130.5(d,J=7.6Hz),129.2,123.9,123.4(d,J=3.0Hz),119.7(d,J=21.1Hz),115.1(d,J=24.2Hz),101.6,67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-111.15(s).HRMS(ESI)calculated for C19H15ClFN4O2[M+H]+,385.0862;found,385.0855.
实施例13化合物H13的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为对氯苯甲酸。得到化合物H13为4-氯-N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H13为淡黄色固体,产率为70%;mp,195-196℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.85(d,J=8.4Hz,2H,Ph-H),7.51(d,J=8.8Hz,2H,Ph-H),7.46(d,J=8.6Hz,2H,Ph-H),7.38(d,J=8.8Hz,2H,Ph-H),4.38(t,J=9.4Hz,2H,-CH2-),3.99(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.7,160.4,139.3,139.2,138.8,133.4,131.1,129.8,129.5,129.3,129.2,129.1,123.9,101.6,67.1,54.0.HRMS(ESI)calculated for C19H15Cl2N4O2[M+H]+,401.0567;found,401.0582.
实施例14化合物H14的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为间氯苯甲酸。得到化合物H14为3-氯-N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
/>
化合物H14为淡黄色固体,产率为70%;mp,203-204℃;1H NMR(600MHz,Chloroform-d)δ7.91(d,J=6.8Hz,2H,Ph-H),7.78(d,J=7.8Hz,1H,Ar-H),7.54(d,J=5.6Hz,1H,Ph-H),7.50(d,J=8.9Hz,2H,Ph-H),7.40(dd,J=22.7,8.4Hz,3H,Ph-H),4.37(t,J=9.4Hz,2H,-CH2-),3.98(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.56,160.38,139.14,138.91,138.61,135.09,134.53,133.49,132.64,130.06,129.22,128.21,125.81,123.99,101.86,67.14,53.94.HRMS(ESI)calculated for C19H15Cl2N4O2[M+H]+,401.0567;found,401.0568.
实施例15化合物H15的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为对溴苯甲酸。得到化合物H15为4-溴-N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H15为淡黄色固体,产率为70%;mp,211-212℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.78(d,J=8.6Hz,2H,Ph-H),7.62(d,J=8.6Hz,2H,Ph-H),7.50(d,J=8.7Hz,2H,Ph-H),7.37(d,J=8.7Hz,2H,Ph-H),4.37(t,J=9.4Hz,2H,-CH2-),3.98(t,J=9.3Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.8,160.5,139.3,138.9,138.8,133.4,132.1,131.6,131.0,129.4,129.2,127.7,123.9,102.1,67.1,54.0.HRMS(ESI)calculated for C19H15BrClN4O2[M+H]+,445.0061;found,445.0070.
实施例16化合物H16的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为间溴苯甲酸。得到化合物H16为3-溴-N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H16为淡黄色固体,产率为70%;mp,193-194℃;1H NMR(600MHz,Chloroform-d)δ8.06(s,1H,Ar-H),7.92(s,1H,Ph-H),7.83(d,J=7.8Hz,1H,Ph-H),7.70(d,J=8.0Hz,1H,Ph-H),7.51(d,J=8.8Hz,2H,Ph-H),7.37(dd,J=18.2,8.3Hz,3H,Ph-H),4.39(t,J=9.4Hz,2H,-CH2-),4.01(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.48,160.37,138.94,138.54,135.57,134.67,133.51,131.14,130.29,129.23,126.27,124.02,123.51,123.01,101.98,67.16,53.90.HRMS(ESI)calculated forC19H15BrClN4O2[M+H]+,445.0061;found,445.0074.
实施例17化合物H17的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为对甲基苯甲酸。得到化合物H17为N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)-4-甲基苯甲酰胺,结构式如下所示:
化合物H17为淡黄色固体,产率为70%;mp,195-196℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.81(d,J=8.3Hz,2H,Ph-H),7.52(d,J=8.6Hz,2H,Ph-H),7.36(d,J=8.7Hz,2H,Ph-H),7.28(d,J=7.9Hz,2H,Ph-H),4.36(t,J=9.4Hz,2H,-CH2-),3.98(t,J=9.4Hz,2H,-CH2-),2.42(s,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ164.6,160.3,143.4,139.5,139.2,138.8,133.2,130.0,129.9,129.5,129.1,127.9,123.8,101.5,67.0,54.1,21.5.HRMS(ESI)calculated for C20H18ClN4O2[M+H]+,381.1113;found,381.1121.
实施例18化合物H18的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为间甲基苯甲酸。得到化合物H18为N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)-3-甲基苯甲酰胺,结构式如下所示:
化合物H18为淡黄色固体,产率为71%;mp,171-172℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H),7.71(d,J=11.4Hz,2H),7.52(d,J=8.8Hz,2H),7.37(dd,J=8.1,3.2Hz,4H),4.36(t,J=9.4Hz,2H),3.99(d,J=9.3Hz,2H),2.40(s,3H).13C NMR(151MHz,Chloroform-d)δ164.91,160.28,139.40,139.04,138.85,138.77,133.43,133.27,132.73,129.17,128.66,124.72,123.88,101.57,67.05,54.06,21.27.HRMS(ESI)calculated for C20H18ClN4O2[M+H]+,381.1113;found,381.1115.
实施例19化合物H19的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为对三氟甲基苯甲酸。得到化合物H19为N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)-4-(三氟甲基)苯甲酰胺,结构式如下所示:
化合物H19为淡黄色固体,产率为62%;mp,201-202℃;1H NMR(600MHz,Chloroform-d)δ8.02(d,J=8.3Hz,2H,Ph-H),7.92(d,J=4.4Hz,1H,Ar-H),7.77–7.68(m,2H,Ph-H),7.53–7.47(m,2H,Ph-H),7.38(dd,J=8.5,4.4Hz,2H,Ph-H),4.37(td,J=9.4,4.3Hz,2H,-CH2-),3.96(td,J=9.5,4.3Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.5,160.5,139.4,139.2,138.9,138.6,136.0,134.3(q,J=33.2Hz),133.6,129.5,129.2,128.3,127.6,125.8(q,J=4.5Hz),125.3(q,J=253.7Hz),124.0,122.6,101.82,67.16,53.94.19F NMR(376MHz,Chloroform-d)δ-63.14(s).HRMS(ESI)calculated forC20H15ClF3N4O2[M+H]+,435.0830;found,435.0834.
实施例20化合物H20的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为间三氟甲基苯甲酸。得到化合物H20为N-(1-(4-氯苯基)-4-(4,5-二氢噁唑-2-基)-1H-吡唑-5-基)-3-(三氟甲基)苯甲酰胺,结构式如下所示:
化合物H20为淡黄色固体,产率为65%;mp,87-88℃;1H NMR(600MHz,Chloroform-d)δ8.22(s,1H,Ar-H),8.10(d,J=7.8Hz,1H,Ph-H),7.92(s,1H,Ph-H),7.83(d,J=7.6Hz,1H,Ph-H),7.63(t,J=7.8Hz,1H,Ph-H),7.52(d,J=8.8Hz,2H,Ph-H),7.39(d,J=8.9Hz,2H,Ph-H),4.39(t,J=9.4Hz,2H,-CH2-),4.01(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.5,160.5,139.3,139.2,138.9,138.7,133.7,133.6,131.5(q,J=33.2Hz),129.5,129.2,129.1(q,J=3.0Hz),128.77,128.6(q,J=247.2Hz),124.94(q,J=4.5Hz),124.1,123.4,101.8,67.2,53.8.19F NMR(376MHz,Chloroform-d)δ-62.89(s).HRMS(ESI)calculated for C20H15ClF3N4O2[M+H]+,435.0830;found,435.0848.
实施例21化合物H21的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼。得到化合物H21为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-4-氟苯甲酰胺,结构式如下所示:
化合物H21为淡黄色固体,产率为73%;mp,137-138℃;1H NMR(600MHz,Chloroform-d)δ7.92(d,J=7.1Hz,3H,Ar-H,Ph-H),7.54(dd,J=21.4,6.3Hz,2H,Ph-H),7.41(t,J=7.8Hz,1H,Ph-H),7.20–7.03(m,3H,Ph-H),4.35(t,J=9.0Hz,2H,-CH2-),3.95(t,J=9.3Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ165.4(d,J=243.1Hz),163.7,161.7(d,J=247.2Hz),160.4,140.6,138.8(d,J=39.3Hz),138.7(d,J=4.5Hz),136.8(d,J=3.0Hz),130.3(d,J=9.1Hz),129.0,127.7,124.7(d,J=7.6Hz),122.8,116.0(d,J=6.0Hz),115.9,115.8(d,J=6.0Hz),115.7,101.7(d,J=27.2Hz),67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-105.91(s),-113.47(s).HRMS(ESI)calculated forC19H15F2N4O2[M+H]+,369.1158;found,369.1174.
实施例22化合物H22的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为间氟苯甲酸。得到化合物H22为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-3-氟苯甲酰胺,结构式如下所示:
化合物H22为淡黄色固体,产率为83%;mp,153-154℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.69(d,J=7.7Hz,1H,Ph-H),7.60(d,J=11.3Hz,1H,Ph-H),7.53(dd,J=7.1,4.8Hz,2H,Ph-H),7.46(d,J=8.1Hz,1H,Ph-H),7.27(d,J=11.6Hz,1H,Ph-H),7.10(t,J=8.5Hz,2H,Ph-H),4.38(t,J=9.4Hz,2H,-CH2-),3.99(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.5,162.8(d,J=247.6Hz),162.6,161.8(d,J=249.2Hz),138.7,136.8(d,J=3.0Hz),135.1(d,J=6.0Hz),130.5(d,J=7.6Hz),124.7(d,J=9.1Hz),123.3(d,J=3.0Hz),119.6(d,J=21.1Hz),115.9(d,J=22.7Hz),115.1(d,J=24.2Hz),101.6,67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-111.21(s),-113.35(s).HRMS(ESI)calculated for C19H15F2N4O2[M+H]+,369.1158;found,369.1164.
实施例23化合物H23的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为对氯苯甲酸。得到化合物H23为4-氯-N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H23为淡黄色固体,产率为80%;mp,169-170℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.84(d,J=8.3Hz,2H,Ph-H),7.53(dd,J=7.3,4.8Hz,2H,Ph-H),7.45(d,J=6.7Hz,2H,Ph-H),7.10(t,J=8.4Hz,2H,Ph-H),4.37(t,J=8.6Hz,2H,-CH2-),3.98(t,J=8.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.7,161.7(d,J=247.6Hz),160.5,139.1,138.9,138.7,136.9,131.2,129.2(d,J=19.6Hz),124.7(d,J=9.1Hz),115.9(d,J=22.7Hz),101.5,67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-113.44(s).HRMS(ESI)calculated for C19H15ClFN4O2[M+H]+,385.0862;found,385.0858.
实施例24化合物H24的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为间氯苯甲酸。得到化合物H24为3-氯-N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H24为淡黄色固体,产率为77%;mp,177-178℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.89(t,J=1.9Hz,1H,Ph-H),7.77(dt,J=7.8,1.4Hz,1H,Ph-H),7.57–7.47(m,3H,Ph-H),7.41(t,J=7.9Hz,1H,Ph-H),7.10(t,J=8.6Hz,2H,Ph-H),4.37(t,J=9.4Hz,2H),3.98(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.5,161.8(d,J=247.6Hz),160.4,138.7,136.8(d,J=3.0Hz),135.1,134.6,132.6,130.1,128.2,125.8,124.7(d,J=7.6Hz),116.0(d,J=22.7Hz),101.7,67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-113.31(s).HRMS(ESI)calculated for C19H15ClFN4O2[M+H]+,385.0862;found,385.0865.
实施例25化合物H25的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为对溴苯甲酸。得到化合物H25为4-溴-N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H25为淡黄色固体,产率为81%;mp,186-187℃;1H NMR(600MHz,Chloroform-d)δ7.90(s,1H,Ar-H),7.77(d,J=5.0Hz,2H,Ph-H),7.57(dd,J=54.5,4.8Hz,4H,Ph-H),7.09(s,2H,Ph-H),4.37(t,J=7.5Hz,2H,-CH2-),3.98(t,J=7.5Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.8,161.7(d,J=249.2Hz),160.5,138.9,138.7,136.9(d,J=4.5Hz),132.1,131.7,129.4,127.6,124.7(d,J=9.1Hz),115.9(d,J=22.7Hz),101.4,67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-113.42(s).HRMS(ESI)calculated for C19H15BrFN4O2[M+H]+,429.0357;found,429.0368.
实施例26化合物H26的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为间溴苯甲酸。得到化合物H26为3-溴-N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H26为淡黄色固体,产率为85%;mp,186-187℃;1H NMR(600MHz,Chloroform-d)δ8.02(s,1H,Ph-H),7.91(s,1H,Ar-H),7.82(d,J=7.8Hz,1H,Ph-H),7.68(d,J=8.2Hz,1H,Ph-H),7.52(s,2H,Ph-H),7.35(t,J=6.6Hz,1H,Ph-H),7.09(s,2H,-CH2-),4.47(t,J=8.0Hz,2H,-CH2-),3.98(t,J=8.0Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.4,161.8(d,J=247.6Hz),160.4,138.7,136.8(d,J=3.0Hz),135.5,134.1,131.1,130.3,126.2,124.7(d,J=9.1Hz),123.0,116.0(d,J=22.6Hz),67.1,54.0.19F NMR(376MHz,Chloroform-d)δ-113.28(s).HRMS(ESI)calculated forC19H15BrFN4O2[M+H]+,429.0357;found,429.0359.
实施例27化合物H27的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为对甲基苯甲酸。得到化合物H27为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-4-甲基苯甲酰胺,结构式如下所示:
化合物H27为淡黄色固体,产率为83%;mp,171-172℃;1H NMR(600MHz,Chloroform-d)δ7.90(s,1H,Ar-H),7.79(s,2H,Ph-H),7.54(s,2H,Ph-H),7.27(s,2H,Ph-H),7.08(s,2H,Ph-H),4.37(t,J=9.9Hz,2H,-CH2-),3.99(t,J=7.7Hz,2H,-CH2-),2.42(s,3H,CH3).13C NMR(151MHz,Chloroform-d)δ164.6,161.6(d,J=246.1Hz),160.4,143.3,139.2,138.7,137.0(d,J=3.0Hz),130.1,129.5,127.9,124.6(d,J=7.6Hz),115.9(d,J=22.7Hz),101.4,67.0,54.1.22.1.19F NMR(376MHz,Chloroform-d)δ-113.75(s).HRMS(ESI)calculated for C20H18FN4O2[M+H]+,365.1408;found,365.1407.
实施例28化合物H28的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为间甲基苯甲酸。得到化合物H28为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-3-甲基苯甲酰胺,结构式如下所示:
化合物H28为淡黄色固体,产率为73%;mp,207-208℃;1H NMR(600MHz,Chloroform-d)δ7.91(s,1H,Ar-H),7.71(s,2H,Ph-H),7.55(s,2H,Ph-H),7.38(s,2H,Ph-H),7.10(d,J=7.9Hz,2H,Ph-H),4.36(t,J=7.3Hz,2H,-CH2-),3.99(t,J=9.3Hz,2H,-CH2-),2.41(d,J=3.1Hz,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ164.9,161.7(d,J=247.6Hz),160.3,139.1,138.7,138.7,137.0(d,J=3.0Hz),133.4,132.8,128.6,124.7,124.6(d,J=9.1Hz),115.9(d,J=24.2Hz),101.5,67.0,21.3.19F NMR(376MHz,Chloroform-d)δ-113.67(s).HRMS(ESI)calculated for C20H18FN4O2[M+H]+,365.1408;found,365.1409.
实施例29化合物H29的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为对三氟甲基苯甲酸。得到化合物H29为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-4-(三氟甲基)苯甲酰胺,结构式如下所示:
化合物H29为淡黄色固体,产率为77%;mp,185-186℃;1H NMR(600MHz,Chloroform-d)δ8.02(d,J=8.1Hz,2H,Ph-H),7.92(s,1H,Ar-H),7.74(d,J=8.1Hz,2H,Ph-H),7.53(dd,J=8.9,4.5Hz,2H,Ph-H),7.11(t,J=8.6Hz,2H,Ph-H),4.39(t,J=9.4Hz,2H,-CH2-),3.99(t,J=9.4Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.4,161.7(d,J=247.6Hz),160.5,138.7,136.8(d,J=3.0Hz),136.0,134.2(q,J=34.7Hz),126.0(q,J=243.1Hz),125.8(q,J=3.0Hz),124.7(d,J=9.1Hz),124.4,122.6,116.0(d,J=6.0Hz),101.6,67.2,54.0.19F NMR(376MHz,Chloroform-d)δ-63.15(s),-113.20(s).HRMS(ESI)calculated for C20H15F4N4O2[M+H]+,419.1126;found,419.1132.
实施例30化合物H30的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为间三氟甲基苯甲酸。得到化合物H30为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-3-(三氟甲基)苯甲酰胺,结构式如下所示:
化合物H30为淡黄色固体,产率为83%;mp,137-138℃;1H NMR(600MHz,Chloroform-d)δ8.22(s,1H,Ph-H),8.09(d,J=7.9Hz,1H,Ar-H),7.92(s,1H,Ph-H),7.82(d,J=7.8Hz,1H,Ph-H),7.63(d,J=7.6Hz,1H,Ph-H),7.54(s,2H,Ph-H),7.16–7.05(m,2H,Ph-H),4.39(t,J=9.5Hz,2H,-CH2-),4.00(t,J=8.9Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ163.5,161.8(d,J=247.6Hz),160.6,139.16,138.77,138.66,136.70(d,J=3.0Hz),133.71,131.5(q,J=33.2Hz),131.0,129.4,129.1(q,J=3.0Hz),124.9(q,J=4.5Hz),124.8(d,J=9.0Hz),123.3(q,J=264.3Hz),116.0(d,J=22.7Hz),121.8,101.8,67.18,53.80.19F NMR(376MHz,Chloroform-d)δ-62.91(s),-113.25(s).HRMS(ESI)calculated for C20H15F4N4O2[M+H]+,419.1126;found,419.1168.
实施例31化合物H31的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氯苯肼,将步骤(7)中的对氟苯甲酸替换为对氯苯甲酸,将步骤(4)中的乙醇胺替换为DL-氨基丙醇。得到化合物H31为4-氯-N-(1-(4-氯苯基)-4-(4-甲基-4,5-二氢噁唑-2-基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H31为白色固体,产率为73%;mp,186-188℃;1H NMR(600MHz,Chloroform-d)δ7.95(s,1H,Ph-H),7.91(s,1H,Ar-H),7.80(d,J=7.8Hz,1H,Ph-H),7.54(d,J=8.2Hz,1H,Ph-H),7.50(d,J=8.4Hz,2H,Ph-H),7.42(d,J=8.0Hz,1H,Ph-H),7.38(d,J=8.3Hz,2H,Ph-H),4.48(t,J=8.7Hz,1H,-CH2),4.35(q,J=7.5Hz,1H,-CH2),3.91(t,J=7.9Hz,1H,-CH),1.33(d,J=6.6Hz,3H,-CH3).13C NMR(151MHz,Chloroform-d)δ163.4,159.4,139.4,138.9,138.8,135.1,134.6,133.4,132.6,130.0,129.2,128.1,125.9,124.0,100.8,73.7,61.2,22.2.HRMS(ESI)calculated for C20H16Cl2N4O2[M+H]+,414.0650;found,414.0658.
实施例32化合物H32的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为甲基肼,将步骤(7)中的对氟苯甲酸替换为苯甲酸。得到化合物H32为N-(4-(4,5-二氢恶唑-2-基)-1-甲基-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
化合物H32为黄色固体,产率为66%;mp,125-126℃;1H NMR(600MHz,Chloroform-d)δ8.09(s,1H,Ar-H),7.55–7.56(m,3H,Ph-H),7.42(d,J=8.5Hz,2H,Ph-H),4.48(t,J=9.4Hz,2H,-CH2),3.96(t,J=9.4Hz,2H,-CH2).13C NMR(151MHz,Chloroform-d)δ165.1,162.6,139.4,128.6,128.5,127.4,127.9,127.5,105.2,68.1,54.7,22.1.HRMS(ESI)calculated for C20H17F47N4O3[M+H]+,270.1117;found,270.1116.
实施例33化合物H33的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为3-肼基吡啶,将步骤(7)中的对氟苯甲酸替换为苯甲酸。得到化合物H33为N-(4-(4,5-二氢噁唑-2-基)-1-(吡啶-3-基)-1H-吡唑-5-基)苯甲酰胺,结构式如下所示:
/>
化合物H33为黄色固体,产率为45%;mp,205-206℃;
1H NMR(600MHz,Chloroform-d)δ8.12(s,1H,Ph-H),8.08(d,J=7.9Hz,1H,Ar-H),7.92(s,1H,Ph-H),7.82(t,J=7.8Hz,2H,Ph-H),7.56(s,1H,Ph-H),7.35–7.38(m,3H,Ph-H),4.34(t,J=9.5Hz,2H,-CH2-),4.05(t,J=8.9Hz,2H,-CH2-).13C NMR(151MHz,Chloroform-d)δ165.4,162.8,150.4,140.6,138.5,136.4,136.9,136.5,128.8,127.1,123.9,121.7,105.0,65.1,54.2.HRMS(ESI)calculated for C20H17F47N4O3[M+H]+,333.1226;found,333.1220.
实施例34化合物H34的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为6-氟烟酸。得到化合物H34为N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)-6-氟烟酰胺,结构式如下所示:
化合物H34为白色固体,产率为63%;mp,184-185℃;1H NMR(600MHz,Chloroform-d)δ8.80(s,1H,Ph-H),8.29(t,J=7.8Hz,1H,Ph-H),7.90(s,1H,Ar-H),7.41(d,J=6.1Hz,2H,Ph-H),7.21(d,J=8.1Hz,2H,Ph-H),6.99(d,J=8.7Hz,1H,Ph-H),4.34(d,J=9.5Hz,2H,-CH2),3.91(t,J=7.9Hz,2H,-CH2),2.36(s,3H,CH3).13C NMR(151MHz,Chloroform-d)δ166.4,164.1,162.7,160.4,148.0,147.9,141.6,141.0,138.6,137.9,137.6,137.2,129.8,122.4,109.3,109.8,101.8,67.3,53.9,21.0.HRMS(ESI)calculated forC19H16FN5O2[M+H]+,365.1288;found,365.1290.
实施例35化合物H35的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为6-氯烟酸。得到化合物H34为6-氯-N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)烟酰胺,结构式如下所示:
化合物H35为黄色固体,产率为70%;mp,172-173℃;1H NMR(600MHz,Chloroform-d)δ8.91(s,1H,Ph-H),8.12(d,J=8.4Hz,1H,Ph-H),7.89(d,J=4.6Hz,1H,Ar-H),7.44–7.37(m,3H,Ph-H),7.21(d,J=6.2Hz,2H,Ph-H),4.39–4.28(m,2H,-CH2),3.89(t,J=16.0Hz,2H,-CH2),2.36(s,3H,CH3).13C NMR(151MHz,Chloroform-d)δ162.2,155.1,149.0,138.9,138.5,137.4,137.0,137.5,129.8,127.1,124.9,122.7,102.1,67.6,53.3,21.1.HRMS(ESI)calculated for C19H16ClN5O2[M+H]+,381.8200;found,381.8195.
实施例36化合物H36的制备
与实施例1不同之处仅在于,将步骤(7)中的对氟苯甲酸替换为3-氯肉桂酸。得到化合物H36为(E)-3-(3-氯苯基)-N-(4-(4,5-二氢噁唑-2-基)-1-(对甲苯基)-1H-吡唑-5-基)丙烯酰胺,结构式如下所示:
化合物H36为黄色固体,产率为59%;mp,155-156℃;1H NMR(600MHz,Chloroform-d)δ7.88(s,1H,Ar-H),7.52(d,J=15.6Hz,1H,Ph-H),7.37(d,J=7.9Hz,3H,Ph-H),7.31(d,J=8.8Hz,2H,Ph-H),7.26(d,J=4.1Hz,1H,-CH),7.21(d,J=8.0Hz,2H,Ph-H),6.50(d,J=15.7Hz,1H,-CH),4.27(t,J=10.4Hz,2H,-CH2),3.82(t,J=9.3Hz,2H,-CH2),2.35(d,J=12.7Hz,3H,CH3).13C NMR(151MHz,Chloroform-d)δ163.6,160.2,139.0,138.8,137.8,137.5,137.4,134.9,132.5,130.8,130.1,129.6,127.4,126.9,123.1,122.1,102.8,66.9,53.9,21.9.HRMS(ESI)calculated for C22H19ClN4O2[M+H]+,406.8700;found,406.8705.
实施例37化合物H37的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为对氟肉桂酸。得到化合物H37为(E)-N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-3-(4-氟苯基)丙烯酰胺,结构式如下所示:
化合物H37为黄色固体,产率为66%;mp,159-160℃;1H NMR(600MHz,Chloroform-d)δ7.89(s,1H,Ar-H),7.55–7.48(m,3H,Ph-H),7.40(d,J=8.5Hz,3H,Ph-H),7.36–7.27(m,3H,Ph-H,-CH),7.11(t,J=8.6Hz,2H,Ph-H),6.51(d,J=15.7Hz,1H,-CH),4.35(t,J=9.4Hz,2H,-CH2),3.95(t,J=9.4Hz,2H,-CH2).13C NMR(151MHz,Chloroform-d)δ163.3,162.6,160.9,160.2,139.3,138.8,135.0,132.5,131.0,130.2,127.64,126.9,124.9,124.9,122.1,116.0,115.8,67.0,54.1.HRMS(ESI)calculated for C21H16F2N4O2[M+H]+,384.3818;found,384.3815.
实施例38化合物H38的制备
与实施例1不同之处仅在于,将步骤(1)中的对甲基苯肼替换为对氟苯肼,将步骤(7)中的对氟苯甲酸替换为扁桃酸。得到化合物H37为N-(4-(4,5-二氢噁唑-2-基)-1-(4-氟苯基)-1H-吡唑-5-基)-2-羟基-2-苯乙酰胺,结构式如下所示:
化合物H38为黄色固体,产率为55%;mp,198-199℃;1H NMR(600MHz,Chloroform-d)δ7.99(s,1H,Ar-H),7.35–7.38(m,3H,Ph-H),7.30(d,J=8.5Hz,2H,Ph-H),7.26(m,4H,Ph-H),5.82(m,H,-CH),5.12(m,H,-CH),4.36(t,J=9.4Hz,2H,-CH2),3.88(t,J=9.4Hz,2H,-CH2).13C NMR(151MHz,Chloroform-d)δ161.1,155.6,149.4,138.6,138.5,137.4,137.9,137.5,129.8,127.1,124.9,122.7,102.0,67.1,53.7.HRMS(ESI)calculated forC20H17F47N4O3[M+H]+,380.1285;found,380.1281.
效果验证例(含噁唑基团的吡唑酰胺类衍生物抗真菌活性的研究)
1实验对象
实施例1-38分别制备的含噁唑基团的吡唑酰胺类衍生物,即化合物H1-化合物H38。
2实验方法
采用菌丝线性生长速率法,测定了化合物H1-化合物H38对灰霉病菌(Botrytiscinerea),烟草赤星病菌(Alternaria alternata),番茄尖镰孢病菌番茄专化型(Fusariumoxysporumf.sp.lyco),苹果腐烂病菌(Valsa mali),玉米小斑病菌(Helminthosporiummaydis),苹果轮纹病菌(Physalosporapiricola),核盘病菌(Sclerotinia scleotiorum)和立枯丝核病菌(Rhizoctonia solani)8种供试植物病原真菌的体外抑制活性。所选真菌由安徽农业大学植物病害防治实验室提供。
以20mg/L的啶菌酰胺溶液为阳性对照,以5%的DMS0水溶液作为空白对照,将已准确称量的待测化合物完全溶于5%的DMSO(v/v)水溶液中(浓度为20mg/L),将10mL待测液或对照液与90mL无菌PDA培养基在50℃快速混匀,得到质量浓度为20mg/L的含药液;将其趁热倒入已灭菌的培养皿内,每皿10mL,冷却备用。把供试植物病原真菌(菌饼直径5mm)接种到上述培养皿中,每个测试组设3个平行;将其置于25℃的恒温培养箱中培养72h后,采用十字交叉法测量菌落直径(mm),按式(1)计算菌丝生长抑制率(IR):IR(%)=[(dc-do)-(ds-do)]/(dc-do)×100(1)。
3实验结果
结果见表1。
表I不同含噁唑基团的吡唑酰胺类衍生物的体外抑菌活性(抑制率%)
注:a值是三次重复的平均标准偏差(SD);bValsa mali(苹果腐烂病菌);cRhizoctonia solani(立枯丝核病菌);dSclerotinia scleotiorum(核盘病菌);eHelminthosporium maydis(玉米小斑病菌);fPhysalosporapiricola(苹果轮纹病菌);gFusarium oxysporumf.sp.lyco(番茄尖镰孢病菌番茄专化型);hAlternaria alternata(烟草赤星病菌);iBotrytis cinerea(灰霉病菌)。
在20mg/L的浓度下初筛了38种含噁唑基团的吡唑酰胺类衍生物(即化合物H1-化合物H38),从表1中分析出,大多数目标化合物对苹果腐烂菌、核盘菌、烟草赤星菌和灰霉菌具有中等至优良的体外抗真菌活性。其中有8种化合物(H1,96.0%;H6,92.0%;H11,92.0%;H13,96.0%;H14,98.0%;H15,94.0%;H16,94.0%;H19,94.0%),其抑制率与啶酰菌胺(96.1%)相当或更高。目标化合物H1(83.1%),H7(90.0%);H13(80.0%)、H14(82.0%)、H15(86.0%)和H16(80.0%)对苹果腐烂菌的抑制率超过80%,与啶酰菌胺相当。此外,化合物H14还对烟草赤星病菌(83.2%)和灰霉病菌(78.0%)表现出广谱抑制活性。另外,将R1取代基替换成甲基(H32)或吡啶环(H33)会导致抗真菌活性的降低;将R2取代基替换成吡啶环(H34和H35)、苯乙烯环(H36和H37)或苯甲醇基(H38)对抗真菌活性的影响值得进一步进行探究。这表明本发明制备的化合物H1-化合物H38有着成为广谱抗真菌剂的潜力。
初步的结构活性关系分析表明,噁唑环的引入明显提高了抗真菌活性,R1和R2取代基的改变显著影响了化合物H1-化合物H38的抗真菌活性。当取代基R1为氯和甲基时,更有利于提升抗真菌活性;在R2取代基上为吸电子基团(如–Cl、Br、–F和–CF3),且R2取代基在间位时,目标化合物对苹果腐烂菌、核盘菌、烟草赤星菌和灰霉菌的抗真菌活性得到了显著提高。
本发明方法制备了38种不同的衍生物,并提供了这些衍生物的化学结构同时还验证了其抗菌活性,具体的:采用浓度20mg/L的含噁唑基团的吡唑酰胺类衍生物用于灰霉病菌、烟草赤星病菌、番茄尖镰孢病菌番茄专化型、苹果腐烂病菌、玉米小斑病菌、苹果轮纹病菌、核盘病菌和立枯丝核病菌8种供试植物病原真菌进行抗菌活性鉴定,结果显示大多数目标化合物对苹果腐烂菌、核盘菌、烟草赤星菌和灰霉菌具有中等至优良的体外抗真菌活性。其中有8种化合物H1(96.0%),H6(92.0%),H11(92.0%);H13(96.0%),H14(98.0%),H15(94.0%),H16(94.0%)和H19(94.0%)对核盘菌的抑制率与啶酰菌胺(96.1%)相当或更高;化合物H1(83.1%),H7(90.0%),H13(80.0%),H14(82.0%),H15(86.0%)和H16(80.0%)对苹果腐烂菌的抑制率超过80%,与啶酰菌胺(83.0%)相当;此外化合物H14还对烟草赤星病菌(83.2%)和灰霉病菌(78.0%)表现出广谱抑制活性。
综合上述,本发明经化学合成制备的38种含噁唑基团的吡唑酰胺类衍生物均具有抗真菌活性,尤其是对苹果腐烂菌、核盘菌、烟草赤星菌和灰霉菌表现出尤为显著的抑菌活性,这为新型琥珀酸脱氢酶抑制剂的进一步开发提供了方向,并且为制备以含噁唑基团的吡唑酰胺类衍生物为主要抗真菌活性成分的杀菌剂奠定了基础。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (1)
1.一种含噁唑基团的吡唑酰胺类衍生物在制备抗真菌药物中的应用,其特征在于,所述含噁唑基团的吡唑酰胺类衍生物的结构式如下所示:
所述的含噁唑基团的吡唑酰胺类衍生物的制备方法包括以下步骤:
将芳香酸、缩合剂、有机溶剂和缚酸剂混合后得到反应体系,将化合物F加入到所述反应体系中反应,萃取得到所述含噁唑基团的吡唑酰胺类衍生物;
所述化合物F的结构式为
其中,R1为R3为氢或烷基;
所述化合物F的制备方法包括以下步骤:
步骤1,将化合物肼与2-氰基-3-乙氧基丙酸酯加入到有机溶剂中进行水解反应得到化合物A;
步骤2,将所述化合物A与碱加入到有机溶剂中进行水解反应,得到化合物B;
步骤3,将所述化合物B溶解于有机溶剂后加入氯化亚砜进行氯代反应,得到化合物C;
步骤4,将所述化合物C和吡啶溶解在有机溶剂中得到混合溶液,向所述混合溶液中滴加醇胺溶液进行取代反应,得到化合物D;
步骤5,将所述化合物D溶解在有机溶剂中,之后加入氯化亚砜进行氯代反应,得到化合物E;
步骤6,将所述化合物E和碱加入到有机溶剂中进行环化反应,得到所述化合物F;
步骤4中,所述化合物C与醇胺的摩尔当量比为1:1-3,取代反应温度为0℃,所述醇胺为乙醇胺或丙醇胺;
步骤5中,所述氯代反应具体为30-40℃条件下反应10-14h,所述化合物D与所述氯化亚砜的摩尔当量比为1:1.2;
步骤6中,所述环化反应具体为50-90℃回流反应3-4h;所述化合物E与碱的摩尔当量比为1:1.5;
所述芳香酸为对氯苯甲酸或间氯苯甲酸;
所述缩合剂为2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯;
所述有机溶剂为二氯甲烷、乙腈、四氢呋喃、甲苯、甲醇、乙醇、乙酸乙酯、1,2-二氯乙烷、N,N-二甲基甲酰胺、N-甲基吡咯烷酮或二甲基亚砜中的一种;
所述缚酸剂为三乙胺或N,N-二异丙基乙胺;
所述化合物F、芳香酸、缩合剂和缚酸剂的摩尔当量比为1:1.2:1.5:1.5;
所述混合后搅拌3小时得到反应体系;
所述反应的过程中利用薄层色谱点板确定反应终点;
所述萃取后还包括依次干燥、抽滤、减压蒸馏和柱层析分离的步骤;
所述水解反应具体为70-85℃回流反应2-4小时,所述化合物肼与2-氰基-3-乙氧基丙酸酯摩尔当量比为1:1-3;
步骤2中,所述水解反应具体为70-80℃回流反应2-4小时;
步骤3中,所述化合物B与所述氯化亚砜摩尔当量比为1:1.25-1.5,所述氯代反应为30-40℃回流反应10-14小时;
所述有机溶剂独立的选自二氯甲烷、乙腈、四氢呋喃、甲苯、甲醇、乙醇、乙酸乙酯、1,2-二氯乙烷、N,N-二甲基甲酰胺、N-甲基吡咯烷酮或二甲基亚砜中的一种;
步骤2中以及步骤6中,所述碱独立的选自碳酸铯、叔丁醇钾、叔丁醇钠、氢氧化钠、氢氧化钾或碳酸钾中的一种;
所述抗真菌药物为抗苹果腐烂病菌、立枯丝核病菌、核盘病菌、玉米小斑病菌、苹果轮纹病菌、番茄尖镰孢病菌番茄专化型、烟草赤星病菌或灰霉病菌的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211070004.8A CN115260176B (zh) | 2022-09-02 | 2022-09-02 | 一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211070004.8A CN115260176B (zh) | 2022-09-02 | 2022-09-02 | 一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115260176A CN115260176A (zh) | 2022-11-01 |
CN115260176B true CN115260176B (zh) | 2024-05-24 |
Family
ID=83754760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211070004.8A Active CN115260176B (zh) | 2022-09-02 | 2022-09-02 | 一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115260176B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4614534A (en) * | 1984-06-22 | 1986-09-30 | Bayer Aktiengesellschaft | 5-amino-4-heterocyclyl-1-phenylpyrazoles |
WO2012102387A1 (ja) * | 2011-01-27 | 2012-08-02 | 日産化学工業株式会社 | ピラゾール誘導体及び有害生物防除剤 |
CN110317204A (zh) * | 2019-08-02 | 2019-10-11 | 安徽农业大学 | 吡唑并嘧啶酮类衍生物及其制备方法和应用 |
CN111187215A (zh) * | 2020-01-21 | 2020-05-22 | 西北农林科技大学 | 含氟吡唑酰胺类衍生物、制备方法及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3604281A4 (en) * | 2017-03-24 | 2020-08-19 | Taisho Pharmaceutical Co., Ltd. | 2 (1H) -CHINOLINONE DERIVATIVE |
-
2022
- 2022-09-02 CN CN202211070004.8A patent/CN115260176B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4614534A (en) * | 1984-06-22 | 1986-09-30 | Bayer Aktiengesellschaft | 5-amino-4-heterocyclyl-1-phenylpyrazoles |
WO2012102387A1 (ja) * | 2011-01-27 | 2012-08-02 | 日産化学工業株式会社 | ピラゾール誘導体及び有害生物防除剤 |
CN110317204A (zh) * | 2019-08-02 | 2019-10-11 | 安徽农业大学 | 吡唑并嘧啶酮类衍生物及其制备方法和应用 |
CN111187215A (zh) * | 2020-01-21 | 2020-05-22 | 西北农林科技大学 | 含氟吡唑酰胺类衍生物、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115260176A (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Novel 4‐pyrazole carboxamide derivatives containing flexible chain motif: design, synthesis and antifungal activity | |
Garudachari et al. | Click chemistry approach: Regioselective one-pot synthesis of some new 8-trifluoromethylquinoline based 1, 2, 3-triazoles as potent antimicrobial agents | |
EP2749555B1 (en) | Method for producing pest controlling agent | |
Desai et al. | Facile synthesis of benzimidazole bearing 2-pyridone derivatives as potential antimicrobial agents | |
Mistry et al. | Synthesis and in vitro antimicrobial and anti-tubercular evaluation of some quinoline-based azitidinone and thiazolidinone analogues | |
HUE027943T2 (en) | Process for the preparation of tetrazole-substituted anthranilic acid amide derivatives and a novel crystalline modification of these derivatives | |
CN105330644B (zh) | (1,2,3,4‑四氢喹啉‑1‑基)(取代吡唑基)甲酮类化合物及其应用 | |
CN104829605A (zh) | 1-取代-5-三氟甲基-4-吡唑联1,3,4-噁二唑硫醚或砜类衍生物及其应用 | |
Miniyar et al. | Synthesis and biological evaluation of 1-(5-(2-chloroquinolin-3-yl)-3-phenyl-1H-pyrazol-1-yl) ethanone derivatives as potential antimicrobial agents | |
Abu‐Melha | Synthesis and antimicrobial activity of some new heterocycles incorporating the pyrazolopyridine moiety | |
CN102993097A (zh) | 吡唑酰胺类化合物及其应用 | |
Vekariya et al. | Microwave-assisted green synthesis of new imidazo [2, 1-b] thiazole derivatives and their antimicrobial, antimalarial, and antitubercular activities | |
Keche et al. | Synthesis, anti-inflammatory and antimicrobial evaluation of novel N1-(quinolin-4yl) ethane-1, 2-diamine phenyl urea derivatives | |
Zhang et al. | Design, synthesis, and insecticidal activity of novel pyrido [1, 2-a] pyrimidinone mesoionic compounds containing an indole moiety as potential acetylcholine receptor insecticides | |
Koch et al. | Compounds Based on a Triethyl-or Trimethoxybenzene Scaffold Bearing Pyrazole, Pyridine, and Pyrimidine Groups: Syntheses and Representative Binding Studies towards Carbohydrates | |
CN115260176B (zh) | 一种含噁唑基团的吡唑酰胺类衍生物及其制备方法和应用 | |
Mahapatra et al. | Design and characterization of Murrayanine linked Isoxazole derivatives: Novel class of bacteriocidal agents | |
Aly et al. | Synthesis of potentially antioxidant and antibacterial biologically active thiazolidines | |
Wu et al. | Synthesis and Bioactivities of Novel 1‐(3‐Chloropyridin‐2‐yl)‐N‐Substituted‐5‐(Trifluoromethyl)‐Pyrazole Carboxamide Derivatives | |
Cheng et al. | Synthesis and Biological Activity of Some New 6‐perfluoropropanyl Quinoline Derivatives | |
Wu et al. | Synthesis and insecticidal activities of novel neonicotinoid analogs bearing an amide moiety | |
KHEDER et al. | Synthesis, in Vitro antimicrobial, anti-liver cancer evaluation of some novel bis-cyanoacrylamide and bis-azoles derivatives | |
Yu et al. | Synthesis and Antifungal and Insecticidal Activities of Novel N‐Phenylbenzamide Derivatives Bearing a Trifluoromethylpyrimidine Moiety | |
CN110317204B (zh) | 吡唑并嘧啶酮类衍生物及其制备方法和应用 | |
Kumar et al. | Synthesis and antimicrobial evaluation of 4-benzylidene-pyrazolidine-3, 5-dione derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |